Quoi de neuf en oncodermatologie ?

[1]  A. Hauschild,et al.  Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.

[2]  V. Sondak,et al.  Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial , 2022, The Lancet.

[3]  Lin F. Yang,et al.  The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet.

[4]  P. Ascierto,et al.  Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. , 2022, The Lancet. Oncology.

[5]  P. Hwu,et al.  Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. , 2022, The Lancet. Oncology.

[6]  D. Schadendorf,et al.  COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Gebski,et al.  Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. , 2022, The Lancet. Oncology.

[8]  C. Lebbé,et al.  Managing immune checkpoint inhibition in transplant recipients. , 2022, The Lancet. Oncology.

[9]  M. Bagot,et al.  Large‐cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases , 2022, The British journal of dermatology.

[10]  A. Lallas,et al.  Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. , 2022, European journal of cancer.

[11]  J. Utikal,et al.  Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Palefsky,et al.  Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. , 2022, The New England journal of medicine.

[13]  C. Huh,et al.  Real-time, In Vivo Skin Cancer Triage by Laser-Induced Plasma Spectroscopy Combined with Deep Learning-based Diagnostic Algorithm. , 2022, Journal of the American Academy of Dermatology.

[14]  K. Shannon,et al.  Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial , 2022, Nature Medicine.

[15]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. , 2022, European journal of cancer.

[16]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.

[17]  C. Lebbé,et al.  IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. , 2022, Cancer cell.

[18]  Nathan E. Reticker-Flynn,et al.  Lymph node colonization induces tumor-immune tolerance to promote distant metastasis , 2022, Cell.

[19]  D. Schadendorf,et al.  CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. , 2022, The New England journal of medicine.

[20]  M. Khodadoust,et al.  Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. , 2022, Blood.

[21]  S. Ai,et al.  Preoperative 3D Reconstruction Model in Slow Mohs Surgery for Dermatofibrosarcoma Protuberans , 2022, Computational intelligence and neuroscience.

[22]  A. Marghoob,et al.  Melanoma with peripheral globules: clinical and dermoscopic features. , 2022, Journal of the American Academy of Dermatology.

[23]  C. Schauer,et al.  Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial , 2022, The Lancet.

[24]  D. Boll,et al.  The Paget Trial: Topical 5% imiquimod cream for non-invasive vulvar Paget disease. , 2022, American journal of obstetrics and gynecology.

[25]  D. Schadendorf,et al.  Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial , 2022, The Lancet.

[26]  F. Bray,et al.  Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. , 2022, JAMA dermatology.

[27]  O. Merimsky,et al.  Phase 2 single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi Sarcoma (cKS). , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  A. Dupuy,et al.  The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy. , 2022, Journal of the National Cancer Institute.

[29]  G. Carcelain,et al.  PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. , 2022, The Lancet. Oncology.

[30]  T. Spector,et al.  Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma , 2022, Nature Medicine.

[31]  D. Schadendorf,et al.  Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. , 2022, European journal of cancer.

[32]  R. Clark,et al.  CCR8 is a new therapeutic target in cutaneous T-cell lymphomas , 2022, Blood advances.

[33]  E. Sattler,et al.  Line-Field Confocal Optical Coherence Tomography: A New Tool for the Differentiation between Nevi and Melanomas? , 2022, Cancers.

[34]  Li Zhou,et al.  Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy , 2022, Melanoma research.

[35]  M. Weichenthal,et al.  Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  K. Shannon,et al.  Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. , 2022, JAMA surgery.

[37]  D. Hartmann,et al.  Line-Field Confocal Optical Coherence Tomography Increases the Diagnostic Accuracy and Confidence for Basal Cell Carcinoma in Equivocal Lesions: A Prospective Study , 2022, Cancers.

[38]  M. Marchetti,et al.  Skin Cancer: Primary, Secondary, and Tertiary Prevention. Part I. , 2022, Journal of the American Academy of Dermatology.

[39]  M. Bagot,et al.  Involvement of the CD39/CD73/adenosine pathway on T cell proliferation and NK cell-mediated ADCC in Sézary syndrome. , 2022, Blood.

[40]  V. Mailänder,et al.  Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma , 2022, Cells.

[41]  L. Biard,et al.  Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome * , 2022, The British journal of dermatology.

[42]  J. Malvehy,et al.  Non-invasive scoring of cellular atypia in keratinocyte cancers in 3D LC-OCT images using Deep Learning , 2022 .

[43]  R. Scolyer,et al.  Dermoscopic features and screening strategies for the detection of small‐diameter melanomas , 2022, Clinical and experimental dermatology.

[44]  D. Schadendorf,et al.  Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. , 2022, The New England journal of medicine.

[45]  U. Wehkamp,et al.  Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop * , 2022, The British journal of dermatology.

[46]  J. Utikal,et al.  Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[47]  P. de la Grange,et al.  Macrophage-derived CXCL9 and CXCL11, T-cell skin homing and disease control in mogamulizumab-treated CTCL patients. , 2021, Blood.

[48]  J. Pearson,et al.  Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. , 2021, Cancer cell.

[49]  D. Schadendorf,et al.  Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Marisa C. Jenkins,et al.  Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. , 2021, JAMA dermatology.

[51]  L. Schwartz,et al.  Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. , 2021, Blood.

[52]  S. Pileri,et al.  Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma , 2021, Cancer.

[53]  I. Johansson,et al.  Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[54]  A. Lallas,et al.  Dermoscopy of nodular/plaque-type primary cutaneous T- and B-cell lymphomas: a retrospective comparative study with pseudolymphomas and tumoral/inflammatory mimickers by the International Dermoscopy Society. , 2021, Journal of the American Academy of Dermatology.

[55]  M. Millward,et al.  Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression , 2021, British Journal of Cancer.

[56]  M. Pindo,et al.  Early melanoma invasivity correlates with gut fungal and bacterial profiles , 2021, The British journal of dermatology.

[57]  Jason M. Johnson,et al.  Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.

[58]  B. Dréno,et al.  Change in lentigo maligna score assessed by in vivo reflectance confocal microscopy after one month of imiquimod treatment for lentigo maligna management. , 2021, Journal of the American Academy of Dermatology.

[59]  A. Lallas,et al.  Dermoscopy of early melanomas: variation according to the anatomic site , 2021, Archives of Dermatological Research.